Actinium Pharmaceuticals begins enrollment in RADIANZ imaging trial for advanced solid tumors
ATNM•Actinium Pharmaceuticals began enrolling patients in RADIANZ, an imaging trial assessing tumor uptake of its HER3-targeting radiotherapy ATNM-400 across advanced solid cancers after standard treatment has failed. Initial prostate cancer results showed no dose-limiting toxicities in the first three patients.
1. Trial enrollment begins
Actinium Pharmaceuticals began enrolling patients in RADIANZ, an imaging trial intended to guide development of its HER3-targeting radiotherapy ATNM-400 beyond prostate cancer. The study will assess tumor uptake across advanced solid cancers in patients whose disease progressed on standard treatment.
2. Early findings and next data
Initial prostate cancer results presented at EANM in October 2026 showed no dose-limiting toxicities in the first three patients, supporting dose escalation. Preclinical findings presented at EANM supported broader cancer development, and additional breast cancer data will be presented at SABCS on December 8-11, 2026.
